NEOG NEOGEN CORP Insider Trading

CEO Nassif Mikheal bought 23 NEOG shares at $10.94 on 2026-02-17; stock at 52-week high, 90-day surge +97.3%.

CEO Nassif Mikheal purchased 23 shares of NEOGEN CORP at $10.94 on 2026-02-17, bringing his holdings to 704 shares (+3.4%). The transaction occurs as NEOG trades at its 52-week high of $10.99 with a +97.3% surge over the past 90 days and +18.8% over the past 30 days. Across his cross-ticker track record, Mikheal's prior four buys averaged a 90-day return of +63.5% with a 100% win rate, though his same-ticker history at NEOG shows mixed near-term performance (one prior buy returned +17.2% in 30 days; another returned -5.0% in 30 days). Notably, NEOG remains unprofitable with a net income of $-15.9M despite $224.7M in quarterly revenue, and the company experienced -3.2% annual revenue contraction, creating a tension between the CEO's accumulation activity and the company's operating fundamentals.

CEO Nassif Mikheal purchased 49 shares across 2 transactions totaling $486.37 at blended avg $9.93, raising stake to 681 shares.

Nassif Mikheal executed 2 separate purchases totaling 49 shares for $486.37 at an average price of $9.93, increasing his holdings by 7.8% from 632 to 681 shares. The stock has appreciated 46.4% over the past 30 days and 69.7% over 90 days, now trading at $10.25, only 11.2% below its 52-week high of $11.54. His prior buy at this ticker on 2025-11-03 generated a 90-day return of +63.5%, demonstrating a history of well-timed entry on this stock. However, NEOG fundamentals remain challenged: the company reported a quarterly revenue of $224,691,000.00 and a net loss of $-15,924,000.00, with annual revenue declining 3.2% year-over-year and full-year net income negative. The timing of these purchases within a sharp uptrend, combined with his track record of favorable 90-day outcomes at this ticker, merits investor monitoring of whether the CEO sees value after the recent rally or is simply accumulating a small position in an operationally stressed business.

NEOG CEO Nassif Mikheal bought 137 shares at $9.33, raising holdings 27.7%; stock is -26.8% from 52-week high amid negative earnings.

Nassif Mikheal, CEO of Neogen Corp, purchased 137 shares at $9.33 on 2026-01-16, increasing his holdings by 27.7% to 632 shares post-transaction. The timing coincides with a notably depressed valuation relative to recent highs: the stock trades at -26.8% from its 52-week high of $12.64, though it has recovered +30.5% over 30 days and +57.3% over 90 days. However, the company's fundamentals remain challenged—net income was $-15.9M (unprofitable) in the most recent quarter, with annual revenue declining 3.2% year-over-year. The CEO's cross-ticker buy history shows limited precision: prior open-market purchases averaged a -5.0% 30-day return, and his one prior NEOG transaction (Buy on 2025-11-03) has not yet registered a measurable 90-day outcome. This purchase represents a meaningful accumulation at current levels but occurs against a backdrop of ongoing operational losses and revenue contraction.

CEO Nassif Mikheal bought 177 NEOG shares at $6.25; holdings up 55.7% to 495 shares post-transaction.

CEO Nassif Mikheal purchased 177 shares at $6.25 on 2025-11-03, increasing his holdings by 55.7% from 318 to 495 shares. The transaction occurred at a price $0.15 below the current market price of $6.40 and significantly below the 52-week high of $16.40, positioning the purchase in the lower portion of the stock's recent trading range. This open-market buy by the CEO comes amid company fundamentals marked by annual revenue decline of -3.2% and negative full-year net income, though the most recent quarter showed positive quarterly results of $209.2M revenue and $36.3M net income. The modest transaction size ($1,106.25 total value) and the company's mixed financial backdrop warrant further examination of the CEO's broader investment thesis and any forward-looking strategic initiatives.

Director Aashima Gupta purchases 16,000 NEOG shares at $6.25; holds 21.9K shares post-transaction (-63.3% from 52-week high).

Director Aashima Gupta purchased 16,000 shares (16.0K shares) at $6.25 on 2025-05-12, increasing her stake by 270.4% from 5,917 shares to 21,917 shares (21.9K shares). The purchase occurred at a price substantially discounted from NEOGEN's 52-week high of $17.71, with the stock currently trading at $6.50, representing a -63.3% decline from its peak. The company is unprofitable, having reported net income of $-10,957,000.00 ($-11.0M) over its most recent full fiscal year, though it has generated annual revenue growth of +12.4%. This acquisition represents a significant increase in the director's absolute holdings, occurring at depressed price levels relative to recent history.

Director James C. Borel buys 30,000 NEOG shares at $4.99; stock down 70.9% from 52-week high amid unprofitability; 6 other insiders bought in past 14 days.

Director James C. Borel purchased 30,000 shares at $4.99 on 2025-04-24, increasing his holdings by 49.6% to 90.5K shares—a substantial discretionary increase. The purchase occurs in a sharply depressed price context: the stock trades at $5.16, down 70.9% from its 52-week high of $17.71, and down 38.8% over the prior 30 days. NEOG is currently unprofitable with net income of $-11.0M despite quarterly revenue of $221.0M, though the company shows 12.4% annual revenue growth. Notably, six other insiders also bought within the past 14 days, forming a cluster acquisition pattern. Borel's prior trade at this ticker (April 2024 buy) yielded a 90-day return of 16.1%, indicating some historical precedent for recovery from depressed valuations at this stock, though the current 70.9% decline from highs represents an extreme departure from normal trading ranges.

Director Woteki buys 5,770 shares of NEOG at $5.17; cluster of 6 other insiders also bought within 14 days amid -70.9% 52-week drawdown

Catherine E Woteki, a director, purchased 5,770 shares at $5.17 on 2025-04-25, increasing her holdings by 77.2% from 7,474 to 13,244 shares. This transaction is part of a cluster pattern: 6 other insiders also bought within the past 14 days. The purchase occurred at a price point significantly below the 52-week high of $17.71 (-70.9%), following a 30-day decline of -38.8% and 90-day decline of -55.0%. The company generated $221.0M in latest-quarter revenue with annual growth of +12.4%, yet reported full-year net income of -$11.0M, indicating recent profitability challenges despite year-over-year revenue expansion. The synchronized buying activity across multiple insiders during sustained price weakness warrants investor attention to whether management's actions signal conviction despite operational headwinds.

Director James C Borel bought 35,000 NEOG shares at $4.89; 6 other insiders bought within 14 days amid -70.6% from 52-week high.

Director Borel purchased 35,000 shares at $4.89, more than doubling his holdings from 25,474 to 60,474 shares. This transaction is part of a broader cluster pattern: 6 other insiders also bought within the past 14 days, suggesting coordinated directional interest from the board. The purchase occurs at a steep discount to recent history—stock is down 70.6% from its 52-week high of $17.71 and down 38.5% over the past 30 days—indicating the purchase was made during acute price weakness. On his prior NEOG buy (2024-04-11), Borel realized a +16.1% 90-day return, demonstrating prior success timing at this ticker. The company, however, remains unprofitable (negative $11.0M net income over its most recent full fiscal year) despite 12.4% annual revenue growth to $221.0M, creating uncertainty about the fundamental catalyst for the cluster buying activity.

Director Boehm buys 5,000 NEOG shares at $5.24; stock now $5.20, down 70.6% from 52-week high of $17.71.

William Boehm, director at Neogen Corp, purchased 5,000 shares at $5.24 on 2025-04-24, increasing his holdings by 16.0% to 36.2K shares post-transaction. The stock is currently trading at $5.20, down 70.6% from its 52-week high of $17.71, and has declined 54.7% over the past 90 days. His prior buy at this ticker on 2023-11-03 showed a 90-day return of -4.7%, with a 0.00% win rate on same-ticker buys. The purchase occurs within a cluster of 6 other insider buys in the past 14 days, and Neogen remains unprofitable with a net loss of $-11.0M in the latest quarter, despite annual revenue growth of 12.4%.

CLO Amy M Rocklin buys 12,500 NEOG shares at $4.99; 4 other insiders also bought within 14 days as stock down 72.2% from 52-week high.

Rocklin, Neogen's Chief Legal Officer, purchased 12,500 shares at $4.99 on April 23, 2025, increasing her holdings by 52.5% to 36,287 shares. This transaction is significant because it coincides with a broader pattern: 4 other insiders bought within the past 14 days, indicating coordinated acquisition activity. The stock is trading at $4.92 (current), down 72.2% from its 52-week high of $17.71 and down 58.1% over the past 90 days, reflecting substantial deterioration in market valuation. Notably, Neogen reported a net loss of $-11.0M on revenue of $221.0M in its latest quarter and was unprofitable over its most recent full fiscal year, suggesting the company is navigating significant operational or profitability challenges even as annual revenue grew 12.4%. The cluster buy pattern by multiple executives during a period of steep stock decline and negative earnings warrants close investor attention to understand the insiders' perspective on valuation or near-term catalysts.